Skip Navigation
Menu
ACP Journal Club |17 January 2017

In adults ≥ 70 years of age, an adjuvanted herpes zoster subunit vaccine reduced herpes zoster at a mean 3.7 years

Henry S. Sacks, PhD, MD

Article, Author, and Disclosure Information
FULL TEXT
Cunningham AL, Lal H, Kovac M, et al; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019-32. 27626517

GIM/FP/GP:

Geriatrics:

Infectious Disease:

In adults ≥ 70 years of age, does a herpes zoster subunit (HZ/su) vaccine reduce herpes zoster compared with placebo? Does it reduce postherpetic neuralgia?
Randomized placebo-controlled trial (Zoster Efficacy Study in Adults 70 Years of Age or Older [ZOE-70]) ClinicalTrials.gov NCT01165229. A prespecified pooled analysis of ZOE-70 and a companion trial in adults ≥ 50 years of age (ZOE-50*, ClinicalTrials.gov NCT01165177) was done...
FULL TEXT
PDF
Not Available
Citations
Citation

Sacks HS. In adults ≥ 70 years of age, an adjuvanted herpes zoster subunit vaccine reduced herpes zoster at a mean 3.7 years. Ann Intern Med. 2017;166:JC5. doi: 10.7326/ACPJC-2017-166-2-005

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2017;166(2):JC5.

DOI: 10.7326/ACPJC-2017-166-2-005

©
2017 American College of Physicians
1 Citations

Related Articles
Cost-Effectiveness of a Vaccine To Prevent Herpes Zoster (Shingles) in Older Adults
Annals of Internal Medicine; 145 (5): I-14
Update in Rheumatology: Evidence Published in 2016
Annals of Internal Medicine; 166 (7): W44-W47
Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial
Annals of Internal Medicine; 152 (9): 545-554
Safety of the Vaccine to Prevent Shingles
Annals of Internal Medicine; 152 (9): I-20
View MoreView Less

Journal Club
In multiple sclerosis, use of fingolimod reduced immune responses to influenza and tetanus booster vaccines
Annals of Internal Medicine; 162 (12): JC8
One or two 7.5-µg doses of MF59-adjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in adults within 21 days
Annals of Internal Medicine; 152 (2): JC1-8
A 15-µg dose of unadjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in healthy adults within 21 days
Annals of Internal Medicine; 152 (2): JC1-9
Human papillomavirus 16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia in young women
Annals of Internal Medicine; 151 (12): JC6-6
View MoreView Less

Related Point of Care
Herpes Zoster
Annals of Internal Medicine; 169 (3): ITC17-ITC32
Travel Medicine
Annals of Internal Medicine; 168 (1): ITC1-ITC16
Herpes Zoster
Annals of Internal Medicine; 154 (5): ITC3-1
Travel Medicine
Annals of Internal Medicine; 156 (11): ITC6-1
View MoreView Less

Related Topics
Infectious Disease
Prevention/Screening
Vaccines/Immunization

Infectious Disease, Prevention/Screening, Vaccines/Immunization.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×